Business
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
SAN FRANCISCO, May 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada.
About this update from Vir Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3057,"height":718,"url":"https://media.zenfs.com/en/business-wire.com/ea8dd544f6ca2f0a60051b500b133a63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xC3x9eeFge4tLm3EdhtDDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNQ--/https://media.zenfs.com/en/business-wire.com/ea8dd544f6ca2f0a60051b500b133a63","width":960,"height":225},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/2kVHEOf0hK0coCJeDcozzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjQ-/https://media.zenfs.com/en/business-wire.com/ea8dd544f6ca2f0a60051b500b133a63","width":1200,"height":282}},"lazy":false},{"type":"text","content":"SAN FRANCISCO, May 05, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada.","length":338,"tagName":"p"},{"type":"text","content":"A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.","length":116,"tagName":"p"},{"type":"text","content":"About Vir Biotechnology","length":23,"tagName":"p"},{"type":"text","content":"Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.","length":615,"tagName":"p"},{"type":"text","content":"Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.","length":189,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/202605...